Skip to main content
SpringerLink
Log in

Deferoxamine (Desferrioxamine)

New Toxicities for an Old Drug

  • Review Article
  • Drug Experience
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Iron is an esssential element for body homoeostasis, but there is no effective mechanism for elimination of an excess of this mineral. Deferoxamine (desferrioxamine) is currently the treatment of choice for iron overload states from both acute iron intoxication and transfusion-dependent anaemias. The pharmacokinetics of deferoxamine are confounded both by its ability to chelate endogenous and exogenous iron and by the laboratory techniques used for its determination. Its iron-complex (ferrioxamine) has different pharmacokinetic properties. Because of its effectiveness, the use of deferoxamine is becoming more common, involving long term and high dose regimens. As a result of this, more and more toxicities that were not known in the past have been described and characterised. The most serious of these include hypotension, renal insufficiency, neurotoxicity, growth retardation and opportunistic infections; some of these side effects may be attributed to or aggravated by ferrioxamine. The pharmacological and toxicological literature on deferoxamine, and possible mechanisms for its toxicity, are reviewed and discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Allain P, Mauras Y, Chaleil D, et al. Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis. British Journal of Clinical Pharmacology 24: 207–212, 1987

    Article  PubMed  CAS  Google Scholar 

  • Balcerzak SP, Jensen WN, Pollack S. Mechanism of action of desferrioxamine on iron absorption. Scandinavian Journal of Haematology 3: 205–212, 1966

    Article  PubMed  CAS  Google Scholar 

  • Barker GA, Brown TCK, Hosking CS. Acute iron poisoning —clinical features and management. Anaesthesia and Intensive Care 4: 345–350, 1974

    Google Scholar 

  • Batey R, Scott J, Jain S, Sherlock S. Acute renal insufficiency occurring during intravenous desferrioxamine therapy. Scandinavian Journal of Haematology 22: 277–279, 1979

    Article  PubMed  CAS  Google Scholar 

  • Bene C, Manzler A, Bene D, Kranias G. Irreversible ocular toxicity from single ‘challenge’ dose of desferrioxamine. Clinical Nephrology 31: 45–48, 1989

    PubMed  CAS  Google Scholar 

  • Bentur Y, Koren G, Klein J, Tesoro A, Leeder JS. Pharmacokinetics of deferoxamine with and without iron load. Veterinary and Human Toxicology 31: 156–157, 1989

    PubMed  CAS  Google Scholar 

  • Bentur Y, Koren G, Tesoro A, et al. Comparison of deferoxamine pharmacokinetics between asymptomatic thalassemic children and those exhibiting severe neurotoxicity. Clinical Pharmacology and Therapeutic, in press, 1990

  • Blake DR, Winyard P, Lunec J, et al. Cerebral and ocular toxicity induced by desferrioxamine. Quarterly Journal of Medicine 56: 345–355, 1985

    PubMed  CAS  Google Scholar 

  • Blatt J, Stitley S. Antineuroblastoma activity of desferioxamine in human cell lines. Cancer Research 47: 1749–1750, 1987

    PubMed  CAS  Google Scholar 

  • Bloomfield SE, Markenson AL, Miller DR, Peterson CM. Lens opacities in thalassemia. Journal of Pediatric Ophthalmology and Stabismus 15: 154–156, 1978

    CAS  Google Scholar 

  • Borgna-Pignatti C, De Stefano P, Broglia AM. Visual loss in patient on high-dose subcutaneous desferrioxamine. Lancet 1: 681, 1984

    Article  PubMed  CAS  Google Scholar 

  • Bouza A, Dominguez A, Meseguer M, et al. Yersinia enterocolitica septicemia. American Journal of Clinical Pathology 74: 404–409, 1980

    PubMed  CAS  Google Scholar 

  • Bowern N, Ramshaw IA, Badenoch-Jones P, Doherty PC. Effect of iron-chelating agent on lymphocyte proliferation. Australian Journal of Experimental Biology and Medical Science 62: 743–754, 1984

    Article  PubMed  CAS  Google Scholar 

  • Brock JH, Ng J. The effect of desferrioxamine on the growth of Staphylococcus aureus, Yersinia enterocolitica and Streptococcuys faecalis in human serum: uptake of desferrioxamine-bound iron. Federation of European Microbiological Societies, Microbiology Letter 20: 439–442, 1983

    Article  CAS  Google Scholar 

  • Brunner H, Peters G, Jaques R. Wirkungen von Desferrioxamine-Methansulfonat auf Kreislauf und Nierenfunktion. Helvetica Physiologica et Pharmacologica Acta 21: C3–6, 1963

    CAS  Google Scholar 

  • Butzler JP, Alexander M, Segers A, Cremer N, Blum D. Enteritis, abscess and septicemia due to Yersinia enterocolitica in a child with thalassemia. Journal of Pediatrics 93: 619–621, 1978

    Article  PubMed  CAS  Google Scholar 

  • Cartei G, Barbui T, Cazzavillan M, Chisei T, Dini E. Desferrioxamine B: reversible side effects of high daily doses. Blut 31: 11–16, 1975

    Article  PubMed  CAS  Google Scholar 

  • Cases A, Kelly J, Sabater J, Campistol JM, Torras A, et al. Acute visual auditory neurotoxicity in patients with end-stage renal disease receiving desferrioxamine. Clinical Nephrology 29: 176–178, 1988

    PubMed  CAS  Google Scholar 

  • Davies SC, Marcus RE, Hungerford JL, Miller MH, Arden GB, et al. Ocular toxicity of high-dose intravenous desferrioxamine. Lancet 2: 181–184, 1983

    Article  PubMed  CAS  Google Scholar 

  • De Virgiliis S, Argiolu F, Sanna G, et al. Auditory involvement in thalassemia major. Acta Haematologica 61: 209–215, 1979

    Article  PubMed  Google Scholar 

  • De Virgiliis S, Congia M, Frau F, et al. Deferoxamine-induced growth retardation in patients with thalassemia major. Journal of Pediatrics 113: 661–669, 1988b

    Article  PubMed  Google Scholar 

  • De Virgiliis S, Congia M, Turco MP, et al. Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassemia. Archives of Disease in Childhood 63: 250–255, 1988a

    Article  PubMed  Google Scholar 

  • Eiser AR, Slifkin RF, Neff MS. Intestinal mucormycosis in hemodialysis patients following deferoxamine. American Journal of Kidney Diseases 10: 71–73, 1987

    PubMed  CAS  Google Scholar 

  • Estrov Z, Cohen A, Gelfand EW, Freedman MH. Cytotoxicity in vitro of deferoxamine on human marrow hematopoietic progenitors. Toxicology In Vitro 2: 131–134, 1988

    Article  PubMed  CAS  Google Scholar 

  • Estrov Z, Tawa A, Wang XH, et al. In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood 69: 757–761, 1987

    PubMed  CAS  Google Scholar 

  • Fischer DS, Parkman R, Fince SC. Acute iron poisoning in children. Journal of the American Medical Association 218: 1179–1184, 1971

    Article  PubMed  CAS  Google Scholar 

  • Freedman MH, Bentur Y, Koren G. Biological and toxic properties of deferoxamine therapy. In Buckner et al. (Eds) Advances and controversies in thalassemia therapy: bone marrow transplantation and other approaches, pp. 115–124, Alan R. Liss, New York, 1989

    Google Scholar 

  • Freedman MH, Boyden M, Taylor M, Skarf B. Neurotoxicity associated with desferrioxamine therapy. Toxicology 49: 283–290, 1988

    Article  PubMed  CAS  Google Scholar 

  • Freedman MH, Grisaru D, Olivieri N, MacLusky I, Thorner PS. Pulmonary syndrome in patients with thalassesmia major receiving intravenous deferoxamine infusions. American Journal of Diseases of Children, in press, 1990

  • Gallant T, Boyden MH, Gallant LA, Carley H, Freedman MH. Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy. American Journal of Medicine 83: 1085–1090, 1987

    Article  PubMed  CAS  Google Scholar 

  • Gallant T, Freedman MH, Velland H, Francombe WH. Yersinia sepsis in patients with iron overload treated with deferoxamine. New England Journal of Medicine 314: 1643, 1986

    PubMed  CAS  Google Scholar 

  • Goodill JJ, Abuelo JG. Mucormycosis —a new risk of deferoxamine therapy in dialysis patients with aluminium or iron overload? New England Journal of Medicine 317: 54, 1987

    PubMed  CAS  Google Scholar 

  • Guerin A, London G, Marchais S, Metivier F, Pelisse JM. Acute deafness and desferrioxamine. Lancet 2: 39–40, 1985

    Article  PubMed  CAS  Google Scholar 

  • Halliwell B, Gutteridge JMC. Free radicals in biology and medicine, Clarendon Press, Oxford, 1985

    Google Scholar 

  • Hay JG, Haslam PL, Turner-Warwick M, Laurent GJ. The effects of iron and desferrioxamine on the lung injury induced by intravenous bleomycin and hyperoxia. Free Radical Research and Communication 4: 109–114, 1987

    Article  CAS  Google Scholar 

  • Hoffbrand AV, Graneshaguru K, Hooton JWL, Tattersall MHN. The effect of iron deficiency and desferrioxamine on DNA synthesis in human cells. British Journal of Haematology 33: 517–526, 1976

    Article  PubMed  CAS  Google Scholar 

  • Hunt J, Richards RJ, Harwood R, Jawbs A. The effect of desferrioxamine on fibroblasts and collagen formation in cell cultures. British Journal of Haematology 41: 69–76, 1979

    Article  PubMed  CAS  Google Scholar 

  • Hwang YF, Brown EB. Effect of desferrioxamine on iron absorption. Lancet 1: 135–137, 1965

    Article  PubMed  CAS  Google Scholar 

  • Jeremy JY, Kontoghiorghes GJ, Hoffbrand AV, Dandona P. The iron chelators desferrioxamine and l-alkyl-2-methyl-3-hydroxypyrid-4-ones inhibit vascular prostacyclin synthesis in vitro. Biochemistry Journal 254: 239–244, 1988

    CAS  Google Scholar 

  • Kattamis C, Ladis V, Vekiou-Samara A. Yersinia enterocolitica infection in patients with β-thalassemia. In Sirchia & Zanella (Eds) Thalassemia today, pp. 591–596, Centro Transfusionale Ospedale Maggiore Policlinico di Milano Editore, Milan, 1987

    Google Scholar 

  • Keberle H. The biochemistry of desferrioxamine and its relation to iron metabolism. Annals of the New York Academy of Sciences 119: 758–768, 1964

    Article  PubMed  CAS  Google Scholar 

  • Koren G, Bentur Y, Strong D, Harvey E, Klein J, et al. Acute renal failure associated with deferoxamine therapy. American Journal of Disease of Children 143: 1077–1080, 1989

    CAS  Google Scholar 

  • Kouides PA, Slapak CA, Rosenwasser LJ, Miller KB. Pneumocystis carinii pneumonia as a complication of desferrioxamine therapy. British Journal of Haematology and Oncology 70: 383–384, 1988

    CAS  Google Scholar 

  • Lakhanpal V, Schocket SS, Jiji S. Deferoxamine (Desferal®)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy. Ophthalmology 91: 443–451, 1984

    PubMed  CAS  Google Scholar 

  • Lederman HM, Cohen A, Lee JWW, Freedman MH, Gelfand EW. Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. Blood 64: 748–753, 1984

    PubMed  CAS  Google Scholar 

  • Leikin S, Vossough P, Mochir-Fatemi F. Chelation therapy in acute iron position. Journal of Pediatrics 71: 425–430, 1967

    Article  PubMed  CAS  Google Scholar 

  • Levine DS, Huebrs HA, Rubin CE, Finch CA. Blocking action of parenteral desferrioxamine on iron absorption in rodents and men. Gastroenterology 95: 1242–1248, 1988

    PubMed  CAS  Google Scholar 

  • Menasché P, Pasquier C, Belluci S, Lorente P, Jaillon P, et al. Deferoxamine reduces neutrophil-mediated free radical production during cardiopulmonary bypass in man. Journal of Thoracic and Cardiovascular Surgery 96: 582–589, 1988

    PubMed  Google Scholar 

  • Meyer-Brunot HG, Keberle H. The metabolism of deferrioxamine B and ferrioxamine B. Biochemical Pharmacology 16: 527–535, 1967

    Article  PubMed  CAS  Google Scholar 

  • Miller KB, Rosenwasser LJ, Bessette J-AM, Beer DJ, Rocklin RE. Rapid desensitization for desferrioxamine anaphylactic reaction. Lancet 1: 1059, 1981

    Article  PubMed  CAS  Google Scholar 

  • Modell B, Berdoukas V (Eds). The clinical approach to thalassemia, Grune & Stratton, Toronto, 1984

    Google Scholar 

  • Moeschlin S, Schnider U. Treatment of primary and secondary hemochromatosis and acute iron poisoning with a new, potent iron-eliminating agent (desferrioxamine-B). New England Journal of Medicine 269: 57–66, 1963

    Article  Google Scholar 

  • Monteagudo FSE, Cassidy MJD, Folb PI. Recent developments in aluminium toxicology. Medical Toxicology 4: 1–6, 1989

    PubMed  CAS  Google Scholar 

  • Olivieri NF, Buncic JR, Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. New England Journal of Medicine 314: 869–873, 1986

    Article  PubMed  CAS  Google Scholar 

  • Pall H, Bloke DR, Winyard P, Lunec J, Williams A, et al. Ocular toxicity of desferrioxamine —an example of copper promoted auto-oxidative damage? British Journal of Ophthalmology 73: 42–47, 1989

    Article  PubMed  CAS  Google Scholar 

  • Peters G, Keberle H, Schmid K, Brunner H. Distribution and renal excretion of desferrioxamine and ferrioxamine in the dog and the rat. Biochemical Pharmacology 15: 93–109, 1966

    Article  PubMed  CAS  Google Scholar 

  • Pippard MJ. Iron chelation in thalassemia. Birth Defects 23: 35–40, 1988

    PubMed  CAS  Google Scholar 

  • Pippard MJ, Callender ST. The management of iron chelation therapy. British Journal of Hematology 54: 503–507, 1983

    Article  CAS  Google Scholar 

  • Polson RJ, Jawed A, Bomford A, Berry H, Williams R. Treatment of rheumatoid arthritis with desferrioxamine: relation between stores of iron before treatment and side effects. British Medical Journal 291: 448, 1985

    Article  PubMed  CAS  Google Scholar 

  • Porter JB, Jaswon MS, Huehns ER, East CA, Hazell JWP. Desferrioxamine toxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. British Journal of Haematology 73: 403–409, 1989

    Article  PubMed  CAS  Google Scholar 

  • Proper R, Nathan D. Clinical removal of iron. Annual Review of Medicine 33: 509–519, 1982

    Article  Google Scholar 

  • Proudfoot AT, Simpson D, Dyson EH. Management of acute iron poisoning. Medical Toxicology 1: 83–100, 1986

    PubMed  CAS  Google Scholar 

  • Rabson AR, Halett AF, Koornhof HJ. Generalised Yersinia enterocolitica infection. Journal of Infectious Diseases 131: 447–451, 1975

    Article  PubMed  CAS  Google Scholar 

  • Rex JH, Ginsberg AM, Fries LF, Pass HI, Kwon-Chung KJ. Cunninghamella bertholletiae infection associated with deferoxamine therapy. Review of Infectious Diseases 10: 1187–1194, 1988

    Article  CAS  Google Scholar 

  • Reynold JEF, Prasad AB (Eds). Martindale: the extra pharmacopeia, 28th ed., pp. 380–393, Pharmaceutical Press, London, 1982

    Google Scholar 

  • Robins-Browne RM, Prpic JK. Effects of iron and desferrioxamine on infections with Yersinia enterocolitica. Infection and Immunity 47: 774–779, 1985

    PubMed  CAS  Google Scholar 

  • Robins-Browne RM, Rabson AR, Koornhof HJ. Generalized infection with Yersinia enterocolitica and the role of iron. Contributions to Microbiology and Immunology 5: 277–282, 1979

    PubMed  CAS  Google Scholar 

  • Robotham JL, Lietman PS. Acute iron poisoning. American Journal of Disease of Children 134: 875–879, 1980

    CAS  Google Scholar 

  • Roche G, Leheup B, Gerard A. Septicémia à Yersinia enterocolitica: revue générale à propos d’un nouveau cas chez une jeune femme présentant une thalassémia majeure. Revue de Medecine Interne 3: 65–74, 1982

    Article  PubMed  CAS  Google Scholar 

  • Rubinstein M, Dupont P, Doppee J-P, Dehon C, Ducobu J, et al. Ocular toxicity of desferrioxamine. Lancet 1: 817–818, 1985

    Article  PubMed  CAS  Google Scholar 

  • Shirane M, Harrison RV. The effects of deferoxamine mesylate and hypoxia on the cochlea. Acta Oto-Laryngologica 104: 99–107, 1987

    Article  PubMed  CAS  Google Scholar 

  • Simon P, Ang KS, Meyrier A, Allain P, Mauras Y. Desferrioxamine, ocular toxicity, and trace metals. Lancet 2: 512–513, 1983

    Article  PubMed  CAS  Google Scholar 

  • Sinclair PR, Granick S. Heme control on the synthesis of Δ-amino levulinic acid synthetase in cultured chick embryo liver cells. Annals of the New York Academy of Sciences 224: 509–520, 1975

    Article  Google Scholar 

  • Sofraniadou K, Drossou M, Foundoulaki L, Konstantopoulos K, Kyriakoy D, et al. Acute bone marrow aplasia associated with intravenous administration of deferoxamine (desferrioxamine). Drug Safety 5: 152–154, 1990

    Article  Google Scholar 

  • Summers MR, Jacobs A, Tudway D, Perera P, Ricketts C. Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. British Journal of Haematology 42: 547–555, 1979

    Article  PubMed  CAS  Google Scholar 

  • Taylor MJ, Keenan NK, Gallant T, Skarf B, Freedman MH, et al. Subclinical VEP abnormalities in patients on chronic deferoxamine therapy: longitudinal studies. Electroencephalography and Clinical Neurophysiology (EEG J) 68: 81–87, 1987

    Article  CAS  Google Scholar 

  • Tenenbein M, Kowalski S, Roberts D. Pulmonary toxicity in iron poisoning: deferoxamine induced? Abstract no. 33. Veterinary and Human Toxicology 32: 34, 1990

    Google Scholar 

  • Tesoro A, Leeder JS, Bentur Y, Klein J, Freedman M, et al. A high-performance liquid Chromatographic method for the measurement of deferoxamine in body fluids. Therapeutic Drug Monitoring 11: 463–470, 1989

    PubMed  CAS  Google Scholar 

  • Tielemans C, Boelaert J, Vergauwe P, van Roost G, Segaert M, et al. Deferoxamine does not increase the risk for bacteremia in hemodialysis patients. Nephron 53: 276–277, 1989

    Article  PubMed  CAS  Google Scholar 

  • Walker JA, Sherman RA, Eisinger RP. Thrombocytopenia associated with intravenous desferrioxamine. American Journal of Kidney Disease 4: 254–256, 1985

    Google Scholar 

  • Ward HE, Hicks M, Nicholson A, Berend N. Deferoxamine infusion does not inhibit bleomycin-induced lung damage in the rat. American Review of Respiratory Disease 137: 1356–1359, 1988

    PubMed  CAS  Google Scholar 

  • Weintrob N, Carley HF, Olivieri NF, Freedman MH, Holland FJ. Effects of early chelation and hypertransfusion on growth and sexual maturation in adolescents with thalassemia major (TM). Abstract no. 554. Pediatric Research 25: 95A, 1989

    Google Scholar 

  • Westlin WF. Deferoxamine in the treatment of acute iron poisoning: clinical experience with 172 children. Clinical Pediatrics 5: 531–535, 1966

    Article  PubMed  CAS  Google Scholar 

  • Westlin WF. Desferrioxamine as a chelating agent. Clinical Toxicology 4: 597–602, 1971

    Article  PubMed  CAS  Google Scholar 

  • White GP, Bailey-Wood R, Jacobs A. The effect of chelating agents on cellular iron metabolism. Clinical Science and Molecular Medicine 50: 145–152, 1976

    PubMed  CAS  Google Scholar 

  • Whitten CF, Chen YC, Gibsen GW. Studies in acute iron poisoning II: further observations on desferrioxamine in the treatment of acute experimental iron poisoning. Pediatrics 38: 102–110, 1966

    PubMed  CAS  Google Scholar 

  • Whitten CF, Gibson GW, Good MH, Goodwin FJ, Brough AJ. Studies in acute iron poisoning, I: desferrioxamine in the treatment of acute iron poisoning; clinical observations, experimental studies, and theoretical considerations. Pediatrics 36: 322–335, 1965

    PubMed  CAS  Google Scholar 

  • Windous DW, Stokes TJ, Julian BA, Fenves AZ. Fatal rhizopus infection in hemodialysis patients receiving deferoxamine. Annals of Internal Medicine 107: 782–785, 1987

    Google Scholar 

  • Wonke B, Hoffbrand AV, Aldouri M, Wickens D, Flynn D, et al. Reversal of desferrioxamine induced auditory neurotoxicity during treatment with Ca-DTPA. Archives of Disease in Childhood 64: 77–82, 1989

    Article  PubMed  CAS  Google Scholar 

  • Zoller KA, Calescibetta CC, Erlbaum AL, Coburn JW. Fatal disseminated phycomycosis (mucormycosis) in patients on deferoxamine for aluminium toxicity. Abstract. American Journal of Kidney Diseases 8: A20, 1986

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Israel Poison Information Center, Rambam Medical Center, Faculty of Medicine, Technion, Haifa, 31096, Israel

    Yedidia Bentur, Michael McGuigan & Gideon Koren

  2. Division of Clinical Pharmacology and Toxicology, Poison Information Center, The Hospital for Sick Children, Toronto, Ontario, Canada

    Yedidia Bentur, Michael McGuigan & Gideon Koren

Authors
  1. Yedidia Bentur
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael McGuigan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gideon Koren
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bentur, Y., McGuigan, M. & Koren, G. Deferoxamine (Desferrioxamine). Drug-Safety 6, 37–46 (1991). https://doi.org/10.2165/00002018-199106010-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199106010-00004

Keywords

Search

Navigation